Behan, F. M. et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature 568, 511–516 (2019).Article ADS CAS PubMed ...
inhibitor
ChemistryCompound 1 (ZINC21803075, D475-1631) was purchased from ChemDiv, and the synthesis of compounds 2–6 is described in the Supplementary Information. Etoposide...
KRAS mutations are among the most frequent gain-of-function alterations found in patients with cancer and their therapeutic targeting has long...
Competing interests G.C.I. received consultancy or advisory role fees from Novartis, Kura Oncology and NuProbe and received research funding from...
Prostate cancer is the most common cancer among men in the United States. Many patients can live long lives due...
Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated...
Scientistsat the University of Michigan Rogel Cancer Center were optimistic when they identified a small molecule that blocked a key...
NLRP3 is an intracellular sensor protein whose activation by a broad spectrum of exogenous and endogenous stimuli leads to inflammasome...
When the COVID-19 pandemic hit, scientists across the U.S. Department of Energy's (DOE) national laboratory complex turned to the nation's...
A protein known as Lefty pumps the brakes as human embryos begin to differentiate into the bones, soft tissues and...